Aktuelle Urol 2004; 35(1): 28-32
DOI: 10.1055/s-2004-822942
Diskussionsforum Urologie

© Georg Thieme Verlag Stuttgart · New York

Pro und Contra der pelvinen Lymphadenektomie beim Prostatakarzinom

Further Information

Publication History

Publication Date:
15 July 2004 (online)

Also available at
 

Der Stellenwert der pelvinen Lymphadenektomie (LA) als Stagingmaßnahme im Rahmen der radikalen Prostatektomie beim Prostatakarzinom (PCA) wird in der Literatur noch immer kontrovers diskutiert. Während einige Autoren auf der Basis von präoperativen Nomogrammen die pelvine Lymphadenektomie nur bei Patienten mit einem hohen Metastasierungsrisiko befürworten, favorisieren andere aufgrund der fehlenden individuellen Verlässlichkeit der Nomogramme die Lymphadenektomie als generelle operative Maßnahme. Erfolgt die pelvine Lymphadenektomie ist die Frage zu klären, ob diese im Sinne der limitierten oder der extendierten Variante erfolgen sollte.

Literatur

  • 1 Gil-Vernet JM.. Prostate cancer: anatomical and surgical considerations.  Brit J Urol. 1996;  78 161-168
    PubMedGoogle Scholar
  • 2 Crawford ED.. Batuello JT.. Snow P.. Gamito EJ.. McLeod DG.. Stone N.. Montie J.. Stock R.. Lynch J.. Brandt J.. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.  Cancer. 2000;  88 2105-2109
    CrossrefPubMedGoogle Scholar
  • 3 Batuello JT.. Gamito EJ.. Crawford ED.. Han M.. Partin AW.. McLeod DG.. Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.  Urology. 2001;  57 481-485
    CrossrefPubMedGoogle Scholar
  • 4 Partin AW.. Kattan MW.. Subing ENP.. Walsh PC.. Wojno KJ.. Oesterling JE.. Combination of prostate-specific antigen, clinical stage, and Gleason sum to predict pathological stage of localized prostate cancer: a multi-institutional update.  JAMA. 1997;  277 1445-1451
    CrossrefPubMedGoogle Scholar
  • 5 Algari M.. Colton MD.. Seidmon ED.. Greenberg RE.. Hanno PM.. The staging pelvic lymphadenectomy: implication as an adjunctive procedure for clinically localized prostate cancer.  J Urol. 1997;  162 243-246
    PubMedGoogle Scholar
  • 6 Bader P.. Burkhard FC.. Markwalder R.. Studer UE.. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a hance of cure?.  J Urol. 2003;  169 849-854
    CrossrefPubMedGoogle Scholar
  • 7 Heidenreich A.. von Knobloch R.. Varga Z.. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy in prostate cancer: high incidence of lymph node metastases.  J Urol. 2001;  167 1681-1684
    PubMedGoogle Scholar
  • 8 Heidenreich A.. von Knobloch R.. Varga Z.. Hofmann R.. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy - data on > 300 cases.  J Urol. 2004; 
    PubMedGoogle Scholar
  • 9 Weingärtner K.. Ramaswamy A.. Bittinger A.. Gerharz EW.. Vöge D.. Riedmiller H.. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic.  J Urol. 1996;  156 1969-1971
    PubMedGoogle Scholar
  • 10 Cheng L.. Zincke H.. Blute ML.. Bergstralh EJ.. Scherer B.. Bostwick DG.. Risk of prostate cancer death in patients with lymph node metastasis.  Cancer. 2001;  91 66-71
    CrossrefPubMedGoogle Scholar
  • 11 Hull HW.. Rabbani F.. Abbas F.. Wheeler TM.. Kattan MW.. Scardino PT.. Cancer control with radical prostatectomy alone in 1000 consecutive patients.  J Urol. 2002;  167 528-534
    CrossrefPubMedGoogle Scholar
  • 12 Narayan P.. Fournier G.. Gajendran V.. Leidich R.. Lo R.. Wolf JS.. Jacob G.. Nicolaisen G.. Palmer K.. Freiha F.. Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.  Urology. 1994;  44 519-524
    CrossrefPubMedGoogle Scholar
  • 13 Bluestein DL.. Bostwick DG.. Bergstralh EJ.. Oesterling JE.. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.  J Urol. 1994;  151 1315-1320
    PubMedGoogle Scholar
  • 14 Conrad S.. Graefen M.. Pichlmaier U.. Henke RP.. Hammerer PG.. Huland H.. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastasis in patients with clinically localized prostate cancer.  J Urol. 1998;  159 2023
    PubMedGoogle Scholar
  • 15 Conrad S.. Graefen M.. Pichlmaier U.. Henke RP.. Ebersdobler A.. Hammerer PG.. Huland H.. Prospective validation of an algoithm with systematic sextant biopsy to predict lymph node metastasis in patients with clinically localized prostate cancer.  J Urol. 2002;  167 521
    PubMedGoogle Scholar
  • 16 Haese A.. Epstein JI.. Huland H.. Partin PW.. Validation of a biopsy based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostatic carcinoma.  Cancer. 2002;  95 1016
    CrossrefPubMedGoogle Scholar
  • 17 Naya Y.. Babaian RJ.. The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.  J Urol. 2003;  170 2306-2310
    PubMedGoogle Scholar
  • 18 Gervasi LA.. Mata J.. Easley JD.. Wilbanks JH.. Seale-Hawkins C.. Carlton Jr. CE. Scardino PT.. Prognostic significance of lymph nodal metastases in prostate cancer.  J Urol. 1989;  142 332-336
    PubMedGoogle Scholar
  • 19 Dillioglugil JF.. Leibman BD.. Leibman NS.. Kattan MW.. Rosas AL.. Scardino PT.. Risk factors for complications and morbidity after radical retropubic prostatectomy.  J Urol. 1997;  157 1760-1767
    PubMedGoogle Scholar
  • 20 Fergany A.. Kupelian PA.. Levin HS.. Zippe CD.. Reddy C.. Klein EA.. No difference in biochemical failure reates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients.  Urology. 2000;  56 92-95
    CrossrefPubMedGoogle Scholar
  • 21 Meng MV.. Carroll PR.. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis.  J Urol. 2000;  164 1235-1240
    PubMedGoogle Scholar
  • 22 El-Galley RES.. Keane TE.. Petros JA.. Sanders WH.. Clarke HS.. Cotsonis GA.. Graham SD.. Evaluation of staging lymphadenectomy in prostate cancer.  Urology. 1998;  52 663-667
    CrossrefPubMedGoogle Scholar
  • 23 Jakse G.. Brehmer B.. Wolf JM.. Aretz R.. Handt S.. Die radikale perineale Prostatektomie ohne Lymphadenektomie.  Urol A. 1999;  38 143-149
    PubMedGoogle Scholar
  • 24 Wawroschek F.. Vogt H.. Weckermann D.. Wagner Th.. Harzmann R.. Radioisotope guided pelvic lymph node dissection for prostate cancer.  J Urol. 2001;  38 1715-1719
    PubMedGoogle Scholar
  • 25 Polasczik TJ.. Manyak MJ.. Haseman MK.. Gurganus RT.. Rogers B.. Maguire RT.. Partin AW.. Comparison of clinical staging algorithms and 111Indium-Capromab Pendetide Immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.  Cancer. 1999;  85 1586-1592
    CrossrefPubMedGoogle Scholar
  • 26 Sodee DB.. Malguria N.. Faulhaber P.. Resnick MI.. Albert J.. Bakale G.. and the Prostacint Imaging Centers. Multicenter Prostacint imaging findings in 2154 patients with prostate cancer.  Urology. 2000;  56 988-993
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. A. HeidenreichLeiter, Bereich für Urologische Onkologie 

Sektion für Urologische Onkologie, Klinik und Poliklinik für Urologie, Medizinische Einrichtungen der Universität zu Köln,

Joseph-Stelzmann-Str. 9

50924 Köln

Email: ab.heidenreich@web.de